Flibanserin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Flibanserin" in English language version.

refsWebsite

Global rank English rank

20nih.gov

4^th place

16doi.org

2^nd place

5nytimes.com

7^th place

4semanticscholar.org

11^th place

8^th place

3fda.gov

447^th place

338^th place

2web.archive.org

1^st place

2hres.ca

low place

1spiegel.de

66^th place

350^th place

1archive.org

6^th place

1reuters.com

49^th place

47^th place

1news-medical.net

8,069^th place

7,681^st place

1sproutpharma.com

low place

1cnn.com

28^th place

26^th place

1npr.org

92^nd place

72^nd place

1forbes.com

54^th place

48^th place

1theatlantic.com

228^th place

158^th place

1arhp.org

low place

1nclnet.org

low place

1ashasexualhealth.org

low place

1newsobserver.com

2,370^th place

1,294^th place

1minnpost.com

8,133^rd place

4,518^th place

1politico.com

312^th place

197^th place

1valeant.com

low place

1bloomberg.com

99^th place

77^th place

1goodrx.com

low place

archive.org

Stahl SM (17 March 2008). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. p. 658. ISBN 978-0-521-67376-1. Retrieved 23 April 2012.

arhp.org

"Association of Reproductive Health Professionals". Retrieved 2015-11-17.

ashasexualhealth.org

"American Sexual Health Association". 19 August 2015. Retrieved 2015-11-17.

bloomberg.com

Edney A, Colbey L (November 17, 2015). "The Female Libido Pill Is No Viagra". Bloomberg Business. Retrieved November 18, 2015.

cnn.com

Landau E (11 February 2014). "FDA: Female sex drive drug needs more research - CNN.com". CNN. Retrieved 31 July 2017.

doi.org

Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). "Pharmacology of flibanserin". CNS Drug Reviews. 8 (2): 117–142. doi:10.1111/j.1527-3458.2002.tb00219.x. PMC 6741686. PMID 12177684.
Jolly E, Clayton A, Thorp J, Lewis-D'Agostino D, Wunderlich G, Lesko L (April 2008). "Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)". Sexologies. 17 (Suppl 1): S133–4. doi:10.1016/S1158-1360(08)72886-X.
Mullard A (October 2015). "FDA approves female sexual dysfunction drug". Nature Reviews. Drug Discovery. 14 (10): 669. doi:10.1038/nrd4757. PMID 26424353. S2CID 36380932.
Simon JA, Clayton AH, Kim NN, Patel S (February 2022). "Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin". Sexual Medicine. 10 (1): 100476. doi:10.1016/j.esxm.2021.100476. PMC 8847820. PMID 34999484.
Rueter LE, de Montigny C, Blier P (August 1998). "In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain". Synapse. 29 (4): 392–405. doi:10.1002/(SICI)1098-2396(199808)29:4<392::AID-SYN11>3.0.CO;2-T. PMID 9661257. S2CID 23093139.
Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). "Pharmacology of flibanserin". CNS Drug Reviews. 8 (2): 117–142. doi:10.1111/j.1527-3458.2002.tb00219.x. PMC 6741686. PMID 12177684.
Stahl SM (February 2015). "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder". CNS Spectrums. 20 (1): 1–6. doi:10.1017/S1092852914000832. PMID 25659981.
Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R (August 2003). "Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors". British Journal of Pharmacology. 139 (7): 1281–1288. doi:10.1038/sj.bjp.0705341. PMC 1573953. PMID 12890707.
Borsini F, Giraldo E, Monferini E, Antonini G, Parenti M, Bietti G, Donetti A (September 1995). "BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex". Naunyn-Schmiedeberg's Archives of Pharmacology. 352 (3): 276–282. doi:10.1007/bf00168557. PMID 8584042. S2CID 19340842.
Stahl SM, Sommer B, Allers KA (January 2011). "Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder". The Journal of Sexual Medicine. 8 (1): 15–27. doi:10.1111/j.1743-6109.2010.02032.x. PMID 20840530.
Scandroglio A, Monferini E, Borsini F (February 2001). "Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors". Pharmacological Research. 43 (2): 179–183. doi:10.1006/phrs.2000.0762. PMID 11243720.
Pfaus JG (June 2009). "Pathways of sexual desire". The Journal of Sexual Medicine. 6 (6): 1506–1533. doi:10.1111/j.1743-6109.2009.01309.x. PMID 19453889. S2CID 3427784.
Allers KA, Dremencov E, Ceci A, Flik G, Ferger B, Cremers TI, et al. (May 2010). "Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study". The Journal of Sexual Medicine. 7 (5): 1757–1767. doi:10.1111/j.1743-6109.2010.01763.x. PMID 20163532.
D'Aquila P, Monleon S, Borsini F, Brain P, Willner P (December 1997). "Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant". European Journal of Pharmacology. 340 (2–3): 121–132. doi:10.1016/S0014-2999(97)01412-X. PMID 9537806.
Torjesen I (21 August 2015). "First drug to improve sexual desire in women approved in the United States". The Pharmaceutical Journal. 295 (7878). doi:10.1211/PJ.2015.20069201.
Gellad WF, Flynn KE, Alexander GC (September 2015). "Evaluation of Flibanserin: Science and Advocacy at the FDA". JAMA. 314 (9): 869–870. doi:10.1001/jama.2015.8405. PMID 26148201.

fda.gov

"June 18, 2010 meeting of the FDA Advisory Committee for Reproductive Health Drugs" (PDF), Minutes, retrieved 2015-11-18
"Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee" (PDF). Food and Drug Administration.

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

forbes.com

"Critics: Women's Sex Pill Approval Vote Driven By PR, Not Science". Forbes. June 7, 2015.

goodrx.com

"Addyi Flibanserin". GoodRx.

hres.ca

hpr-rps.hres.ca

"Search Page - Drug and Health Product Register". 23 October 2014.

pdf.hres.ca

"ADDYI Product Monograph" (PDF). Health Canada. January 26, 2021. Retrieved November 14, 2022.

minnpost.com

Perry P (8 June 2015). "'Faux-advocacy,' not science, prompted FDA panel's OK of 'low libido' drug for women, critics charge". minnpost.com. Retrieved 18 August 2015.

nclnet.org

"National Consumers League". 4 June 2015. Retrieved 2015-11-17.

news-medical.net

"Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women". 27 June 2013.

newsobserver.com

"Raleigh's Sprout Pharmaceuticals awaits FDA ruling on female libido drug | News & Observer".

nih.gov

pubmed.ncbi.nlm.nih.gov

Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). "Pharmacology of flibanserin". CNS Drug Reviews. 8 (2): 117–142. doi:10.1111/j.1527-3458.2002.tb00219.x. PMC 6741686. PMID 12177684.
Mullard A (October 2015). "FDA approves female sexual dysfunction drug". Nature Reviews. Drug Discovery. 14 (10): 669. doi:10.1038/nrd4757. PMID 26424353. S2CID 36380932.
Simon JA, Clayton AH, Kim NN, Patel S (February 2022). "Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin". Sexual Medicine. 10 (1): 100476. doi:10.1016/j.esxm.2021.100476. PMC 8847820. PMID 34999484.
Rueter LE, de Montigny C, Blier P (August 1998). "In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain". Synapse. 29 (4): 392–405. doi:10.1002/(SICI)1098-2396(199808)29:4<392::AID-SYN11>3.0.CO;2-T. PMID 9661257. S2CID 23093139.
Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). "Pharmacology of flibanserin". CNS Drug Reviews. 8 (2): 117–142. doi:10.1111/j.1527-3458.2002.tb00219.x. PMC 6741686. PMID 12177684.
Stahl SM (February 2015). "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder". CNS Spectrums. 20 (1): 1–6. doi:10.1017/S1092852914000832. PMID 25659981.
Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R (August 2003). "Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors". British Journal of Pharmacology. 139 (7): 1281–1288. doi:10.1038/sj.bjp.0705341. PMC 1573953. PMID 12890707.
Borsini F, Giraldo E, Monferini E, Antonini G, Parenti M, Bietti G, Donetti A (September 1995). "BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex". Naunyn-Schmiedeberg's Archives of Pharmacology. 352 (3): 276–282. doi:10.1007/bf00168557. PMID 8584042. S2CID 19340842.
Stahl SM, Sommer B, Allers KA (January 2011). "Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder". The Journal of Sexual Medicine. 8 (1): 15–27. doi:10.1111/j.1743-6109.2010.02032.x. PMID 20840530.
Scandroglio A, Monferini E, Borsini F (February 2001). "Ex vivo binding of flibanserin to serotonin 5-HT1A and 5-HT2A receptors". Pharmacological Research. 43 (2): 179–183. doi:10.1006/phrs.2000.0762. PMID 11243720.
Pfaus JG (June 2009). "Pathways of sexual desire". The Journal of Sexual Medicine. 6 (6): 1506–1533. doi:10.1111/j.1743-6109.2009.01309.x. PMID 19453889. S2CID 3427784.
Allers KA, Dremencov E, Ceci A, Flik G, Ferger B, Cremers TI, et al. (May 2010). "Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study". The Journal of Sexual Medicine. 7 (5): 1757–1767. doi:10.1111/j.1743-6109.2010.01763.x. PMID 20163532.
D'Aquila P, Monleon S, Borsini F, Brain P, Willner P (December 1997). "Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant". European Journal of Pharmacology. 340 (2–3): 121–132. doi:10.1016/S0014-2999(97)01412-X. PMID 9537806.
Gellad WF, Flynn KE, Alexander GC (September 2015). "Evaluation of Flibanserin: Science and Advocacy at the FDA". JAMA. 314 (9): 869–870. doi:10.1001/jama.2015.8405. PMID 26148201.

ncbi.nlm.nih.gov

Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). "Pharmacology of flibanserin". CNS Drug Reviews. 8 (2): 117–142. doi:10.1111/j.1527-3458.2002.tb00219.x. PMC 6741686. PMID 12177684.
Simon JA, Clayton AH, Kim NN, Patel S (February 2022). "Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin". Sexual Medicine. 10 (1): 100476. doi:10.1016/j.esxm.2021.100476. PMC 8847820. PMID 34999484.
Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (2002). "Pharmacology of flibanserin". CNS Drug Reviews. 8 (2): 117–142. doi:10.1111/j.1527-3458.2002.tb00219.x. PMC 6741686. PMID 12177684.
Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R (August 2003). "Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors". British Journal of Pharmacology. 139 (7): 1281–1288. doi:10.1038/sj.bjp.0705341. PMC 1573953. PMID 12890707.

dailymed.nlm.nih.gov

"Addyi- flibanserin tablet, film coated". DailyMed. 10 October 2019. Retrieved 20 October 2020.
"ADDYI- flibanserin tablet, film coated". DailyMed. September 1, 2021. Retrieved November 14, 2022.

npr.org

Stein R (June 4, 2015). "Advisers To FDA Recommend Agency Approve Drug To Boost Female Libido". NPR. Retrieved June 4, 2015.

nytimes.com

Nagoski E (27 February 2015). "Nothing Is Wrong With Your Sex Drive". The New York Times. Retrieved 31 July 2017.
"Drug for sexual desire disorder opposed by panel". The New York Times. 18 June 2010.
Pollack A (2015-06-04). "'Viagra for Women' Is Backed by an F.D.A. Panel". The New York Times.
Pollack A (18 August 2015). "F.D.A. Approves Addyi, a Libido Pill for Women". The New York Times.
Thomas K (9 April 2016). "The Female Viagra, Undone by a Drug Maker's Dysfunction". The New York Times. Retrieved 9 April 2016.

politico.com

Karlin S (13 August 2015). "Women's sex drug gets political hard sell". politico.com. Retrieved 18 August 2015.

reuters.com

Burger L (8 October 2010). "Boehringer pulls the plug on "pink Viagra"". Reuters.

semanticscholar.org

api.semanticscholar.org

Mullard A (October 2015). "FDA approves female sexual dysfunction drug". Nature Reviews. Drug Discovery. 14 (10): 669. doi:10.1038/nrd4757. PMID 26424353. S2CID 36380932.
Rueter LE, de Montigny C, Blier P (August 1998). "In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain". Synapse. 29 (4): 392–405. doi:10.1002/(SICI)1098-2396(199808)29:4<392::AID-SYN11>3.0.CO;2-T. PMID 9661257. S2CID 23093139.
Borsini F, Giraldo E, Monferini E, Antonini G, Parenti M, Bietti G, Donetti A (September 1995). "BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex". Naunyn-Schmiedeberg's Archives of Pharmacology. 352 (3): 276–282. doi:10.1007/bf00168557. PMID 8584042. S2CID 19340842.
Pfaus JG (June 2009). "Pathways of sexual desire". The Journal of Sexual Medicine. 6 (6): 1506–1533. doi:10.1111/j.1743-6109.2009.01309.x. PMID 19453889. S2CID 3427784.

spiegel.de

Spiegel online: Pharmakonzern stoppt Lustpille für die Frau, 8 October 2010 (in German)

sproutpharma.com

"ADDYI® (flibanserin) - Home". sproutpharma.com. Archived from the original on 10 August 2015. Retrieved 31 July 2017.

theatlantic.com

"Why Flibanserin Is Not the 'Female Viagra' - The Atlantic". The Atlantic. 19 August 2015.

valeant.com

ir.valeant.com

"Valeant - Valeant Pharmaceuticals to Acquire Sprout Pharmaceuticals". Archived from the original on 2015-08-22. Retrieved 2015-10-25.

web.archive.org

"ADDYI® (flibanserin) - Home". sproutpharma.com. Archived from the original on 10 August 2015. Retrieved 31 July 2017.
"Valeant - Valeant Pharmaceuticals to Acquire Sprout Pharmaceuticals". Archived from the original on 2015-08-22. Retrieved 2015-10-25.